Zacks Investment Research disclosed Celgene Corporation (NASDAQ:CELG), boosting its price target to $117.00 earlier today
- Updated: October 7, 2016
Reporting a potential upside of 0.12%, Zacks Investment Research upped the price target of Celgene Corporation (NASDAQ:CELG) to $117.00
On 9/29/2016, Citigroup released a statement about Celgene Corporation (NASDAQ:CELG) upped the target price from $124.00 to $127.00 that suggested an upside of 0.23%.
Having a price of $104.03, Celgene Corporation (NASDAQ:CELG) traded 0.04% higher on the day. With the last stock price down -1.36% from the two hundred day average, compared with the Standard & Poor's 500 Index which has decreased -0.01% over the same period. CELG has recorded a 50-day average of $107.29 and a two hundred day average of $105.50. Volume of trade was down over the average, with 1,871,956 shares of CELG changing hands under the typical 4,032,960
With a market cap of $0, Celgene Corporation has 52 week low of $93.05 and a 52 week high of $128.39 with a P/E ratio of 43.99 .
In addition to Zacks Investment Research reporting its target price, a total of 22 firms have issued a report on the stock. The consensus target price is $136.82 with 10 firms rating the stock a strong buy, 10 firms rating the stock a buy, 4 firms rating the stock a hold, 1 firm rating the stock a underperform, and finally 0 firms rating the stock a sell.
About Celgene Corporation (NASDAQ:CELG)
Celgene Corporation (Celgene) is a biopharmaceutical company. The Company together with its subsidiaries is engaged primarily in the discovery, development and commercialization of therapies for the treatment of cancer and inflammatory diseases through solutions in protein homeostasis, immuno-oncology, epigenetics, immunology and neuro-inflammation. The Company's primary commercial stage products include REVLIMID (lenalidomide), ABRAXANE (paclitaxel albumin-bound particles for injectable suspension), POMALYST/IMNOVID (pomalidomide), VIDAZA, azacitidine for injection (generic version of VIDAZA), THALOMID (thalidomide), OTEZLA (apremilast) and ISTODAX (romidepsin). The Company's clinical trial activity includes trials across the disease areas of hematology, oncology, and inflammation and immunology.
Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with MarketBeat.com's FREE daily email newsletter.